GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » EV-to-EBIT

Chong Kun Dang Pharmaceutical (XKRX:185750) EV-to-EBIT : 4.70 (As of May. 22, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Chong Kun Dang Pharmaceutical's Enterprise Value is ₩931,978 Mil. Chong Kun Dang Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₩198,297 Mil. Therefore, Chong Kun Dang Pharmaceutical's EV-to-EBIT for today is 4.70.

The historical rank and industry rank for Chong Kun Dang Pharmaceutical's EV-to-EBIT or its related term are showing as below:

XKRX:185750' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.06   Med: 14.03   Max: 87.13
Current: 4.7

During the past 12 years, the highest EV-to-EBIT of Chong Kun Dang Pharmaceutical was 87.13. The lowest was 4.06. And the median was 14.03.

XKRX:185750's EV-to-EBIT is ranked better than
90.83% of 698 companies
in the Drug Manufacturers industry
Industry Median: 16.39 vs XKRX:185750: 4.70

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Chong Kun Dang Pharmaceutical's Enterprise Value for the quarter that ended in Mar. 2025 was ₩1,027,544 Mil. Chong Kun Dang Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was ₩198,297 Mil. Chong Kun Dang Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 19.30%.


Chong Kun Dang Pharmaceutical EV-to-EBIT Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical EV-to-EBIT Chart

Chong Kun Dang Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.27 15.33 9.92 5.74 9.63

Chong Kun Dang Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.84 4.53 5.99 9.63 5.18

Competitive Comparison of Chong Kun Dang Pharmaceutical's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Chong Kun Dang Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chong Kun Dang Pharmaceutical's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chong Kun Dang Pharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chong Kun Dang Pharmaceutical's EV-to-EBIT falls into.


;
;

Chong Kun Dang Pharmaceutical EV-to-EBIT Calculation

Chong Kun Dang Pharmaceutical's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=931977.714/198296.814
=4.70

Chong Kun Dang Pharmaceutical's current Enterprise Value is ₩931,978 Mil.
Chong Kun Dang Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩198,297 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chong Kun Dang Pharmaceutical  (XKRX:185750) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Chong Kun Dang Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=198296.814/1027544.289
=19.30 %

Chong Kun Dang Pharmaceutical's Enterprise Value for the quarter that ended in Mar. 2025 was ₩1,027,544 Mil.
Chong Kun Dang Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩198,297 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chong Kun Dang Pharmaceutical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Chong Kun Dang Pharmaceutical Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical Headlines

No Headlines